Open AccessMetastatic renal cell carcinoma: the first report of unilateral fundus hemorrhage induced by sorafenib
Author(s) -
Zhi Yong Li,
Xin Fan,
Yan Jun Wang,
Kai Yao,
Zhuo Wei Liu,
Wen Tao Pan,
Yun Lin Ye,
Ping Yang,
Yi Huang,
Zhiyuan Wu,
Fang Zhou
Publication year - 2016
Publication title -
oncotarget
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.373
H-Index - 127
ISSN - 1949-2553
DOI - 10.18632/oncotarget.9285
Subject(s) - medicine , sorafenib , renal cell carcinoma , sunitinib , incidence (geometry) , kidney cancer , cancer , traditional medicine , oncology , hepatocellular carcinoma , physics , optics
Renal cell carcinoma (RCC) is the most common type of kidney tumor with increasing incidence. Tyrosine Kinase Inhibitors (TKIs) are considered important treatment in the management of metastatic RCC. Some previous studies demonstrated that sorafenib treatment is associated with a significantly increased risk of potentially life-threatening adverse events, like bleeding. But bleeding at the fundus site is the rarest type of hemorrhage. As for TKIs' risk of bleeding, how we distinguish the degree of bleeding and what optimal strategies should we take to manage bleeding, needs to be studied systematically.